215 related articles for article (PubMed ID: 31712971)
1. S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial.
Sarris J; Murphy J; Stough C; Mischoulon D; Bousman C; MacDonald P; Adams L; Nazareth S; Oliver G; Cribb L; Savage K; Menon R; Chamoli S; Berk M; Ng CH; Byrne GJ
Psychopharmacology (Berl); 2020 Jan; 237(1):209-218. PubMed ID: 31712971
[TBL] [Abstract][Full Text] [Related]
2. Adjunctive S-adenosylmethionine (SAMe) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial.
Sarris J; Byrne GJ; Bousman C; Stough C; Murphy J; MacDonald P; Adams L; Nazareth S; Oliver G; Cribb L; Savage K; Menon R; Chamoli S; Berk M; Ng C; Mischoulon D
Eur Neuropsychopharmacol; 2018 Oct; 28(10):1126-1136. PubMed ID: 30115553
[TBL] [Abstract][Full Text] [Related]
3. Nutraceuticals for major depressive disorder- more is not merrier: An 8-week double-blind, randomised, controlled trial.
Sarris J; Byrne GJ; Stough C; Bousman C; Mischoulon D; Murphy J; Macdonald P; Adams L; Nazareth S; Oliver G; Cribb L; Savage K; Menon R; Chamoli S; Berk M; Ng CH
J Affect Disord; 2019 Feb; 245():1007-1015. PubMed ID: 30699842
[TBL] [Abstract][Full Text] [Related]
4. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
[TBL] [Abstract][Full Text] [Related]
5. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial.
Baune BT; Sampson E; Louise J; Hori H; Schubert KO; Clark SR; Mills NT; Fourrier C
Eur Neuropsychopharmacol; 2021 Dec; 53():34-46. PubMed ID: 34375789
[TBL] [Abstract][Full Text] [Related]
6. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
[TBL] [Abstract][Full Text] [Related]
7. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
[TBL] [Abstract][Full Text] [Related]
8. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
9. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
10. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
[TBL] [Abstract][Full Text] [Related]
12. Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial.
McAllister-Williams RH; Anderson IM; Finkelmeyer A; Gallagher P; Grunze HC; Haddad PM; Hughes T; Lloyd AJ; Mamasoula C; McColl E; Pearce S; Siddiqi N; Sinha BN; Steen N; Wainwright J; Winter FH; Ferrier IN; Watson S;
Lancet Psychiatry; 2016 Feb; 3(2):117-27. PubMed ID: 26727041
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
Weisler RH; Montgomery SA; Earley WR; Szamosi J; Lazarus A
Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial.
Berk M; Dean OM; Cotton SM; Jeavons S; Tanious M; Kohlmann K; Hewitt K; Moss K; Allwang C; Schapkaitz I; Robbins J; Cobb H; Ng F; Dodd S; Bush AI; Malhi GS
J Clin Psychiatry; 2014 Jun; 75(6):628-36. PubMed ID: 25004186
[TBL] [Abstract][Full Text] [Related]
15. S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response.
Sarris J; Papakostas GI; Vitolo O; Fava M; Mischoulon D
J Affect Disord; 2014 Aug; 164():76-81. PubMed ID: 24856557
[TBL] [Abstract][Full Text] [Related]
16. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
[TBL] [Abstract][Full Text] [Related]
17. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial.
Ravindran AV; Kennedy SH; O'Donovan MC; Fallu A; Camacho F; Binder CE
J Clin Psychiatry; 2008 Jan; 69(1):87-94. PubMed ID: 18312042
[TBL] [Abstract][Full Text] [Related]
18. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.
Pancheri P; Scapicchio P; Chiaie RD
Int J Neuropsychopharmacol; 2002 Dec; 5(4):287-94. PubMed ID: 12466028
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
[TBL] [Abstract][Full Text] [Related]
20. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
Bauer M; Pretorius HW; Constant EL; Earley WR; Szamosi J; Brecher M
J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
